SCA
COGT icon

Snowden Capital Advisors’s Cogent Biosciences COGT Stock Holding History

Snowden Capital Advisors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$202K Buy
+5,252
New +$194K 0.01% 1222

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Snowden Capital Advisors's COGT Position: Q1 2026 in Review

Snowden Capital Advisors opened a new position in Cogent Biosciences (COGT) in Q1 2026: 5,252 shares worth $202K. The stake represents 0.01% of the portfolio and ranks #1222 among its holdings.

305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Snowden Capital Advisors held 5,252 shares of Cogent Biosciences worth $202K as of Q1 2026.
  • Cogent Biosciences was a new Snowden Capital Advisors position in Q1 2026.
  • Cogent Biosciences made up 0.01% of Snowden Capital Advisors's portfolio in Q1 2026, its #1222 holding.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Snowden Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.